Heidelberg Pharma AG (HPHA) - Total Liabilities
Based on the latest financial reports, Heidelberg Pharma AG (HPHA) has total liabilities worth €43.94 Million EUR (≈ $51.37 Million USD) as of May 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Heidelberg Pharma AG - Total Liabilities Trend (2016–2024)
This chart illustrates how Heidelberg Pharma AG's total liabilities have evolved over time, based on quarterly financial data. See HPHA working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Heidelberg Pharma AG Competitors by Total Liabilities
The table below lists competitors of Heidelberg Pharma AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ekter SA
AT:EKTER
|
Greece | €43.52 Million |
|
K2 Capital Acquisition Corporation
NASDAQ:KTWO
|
USA | $272.00K |
|
ADC Therapeutics SA
NYSE:ADCT
|
USA | $507.87 Million |
|
Waton Financial Limited Ordinary Shares
NASDAQ:WTF
|
USA | $5.31 Million |
|
BANK OF JIUJIANG H YC1
F:BJ8
|
Germany | €474.81 Billion |
|
CBO Territoria S.A.
PA:CBOT
|
France | €227.60 Million |
|
WRKR Ltd
AU:WRK
|
Australia | AU$73.64 Million |
|
Orion Minerals Ltd
AU:ORN
|
Australia | AU$59.95 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Heidelberg Pharma AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Heidelberg Pharma AG market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Heidelberg Pharma AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Heidelberg Pharma AG (2016–2024)
The table below shows the annual total liabilities of Heidelberg Pharma AG from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-11-30 | €29.85 Million ≈ $34.90 Million |
+42.08% |
| 2023-11-30 | €21.01 Million ≈ $24.57 Million |
-38.08% |
| 2022-11-30 | €33.94 Million ≈ $39.68 Million |
+125.75% |
| 2021-11-30 | €15.03 Million ≈ $17.58 Million |
+123.39% |
| 2020-11-30 | €6.73 Million ≈ $7.87 Million |
+0.49% |
| 2019-11-30 | €6.70 Million ≈ $7.83 Million |
+26.22% |
| 2018-11-30 | €5.31 Million ≈ $6.20 Million |
+18.81% |
| 2017-11-30 | €4.47 Million ≈ $5.22 Million |
-18.58% |
| 2016-11-30 | €5.49 Million ≈ $6.41 Million |
-- |
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, the United States, and internationally. Its lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company develops HDP-102, an antibody and the compound Amaniti… Read more